Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Hematopoietic stem cell transplantation (HSCT) offers curative potential for various diseases.
• Enhancing stem cell collection efficiency and graft quality is crucial for improving HSCT outcomes and expanding the donor pool.

Purpose of the Study:

• To develop a rapid and efficient stem cell mobilization regimen for HSCT.
• To investigate the mechanisms underlying rapid stem cell mobilization and assess graft quality.

Main Methods:

• Developed a mobilization regimen combining a CXCR2 agonist (GROβ) and a CXCR4 antagonist (AMD3100).
• Administered a single injection of the combined agents to assess stem cell mobilization kinetics and magnitude.
• Conducted mechanistic studies involving neutrophil signaling, MMP-9 release, and analysis of MMP-9 genetic polymorphisms.
• Evaluated the engraftment efficiency of mobilized stem cells in preclinical models.

Main Results:

• A single injection of GROβ and AMD3100 induced rapid stem cell mobilization peaking within 15 minutes.
• The magnitude of mobilization was comparable to standard multi-day granulocyte colony-stimulating factor (G-CSF) regimens.
• Mobilization involved synergistic signaling on neutrophils, leading to enhanced matrix metalloproteinase-9 (MMP-9) release.
• Unexpectedly identified genetic polymorphisms in MMP-9 affecting its activity.
• Stem cells mobilized by this regimen showed preferential trafficking and higher engraftment efficiency than G-CSF-mobilized cells.

Conclusions:

• The novel GROβ and AMD3100 regimen provides a rapid and effective strategy for hematopoietic stem cell mobilization.
• This approach yields a superior graft with enhanced engraftment potential.
• Further investigation into MMP-9 polymorphisms may offer additional insights into stem cell mobilization and graft enhancement.